GENI Share Price Performance
UK£0
-0.02 (-100.00%)
Price UK£0
Fair ValueUK£0.075
Share Pricen/a
GENinCode Plc Stock Price
- 1 Narratives written by author
- 0 Comments on narratives written by author
- 1 Fair Values set on narratives written by author
GENI Community Narratives
AN
Fair Value
·Fair Value UK£0.075 89.3% undervalued intrinsic discount
Future Clinical Acceptance Of Genetic Risk Scoring Will Support Long Term Earnings Potential
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
Future Clinical Acceptance Of Genetic Risk Scoring Will Support Long Term Earnings Potential
Catalysts About GENinCode GENinCode develops and commercialises genetic tests that aim to improve risk assessment and prevention in cardiovascular disease and certain cancers. What are the underlying business or industry changes driving this perspective?Read more
AN
UK£0.075
89.3% undervalued intrinsic discount
Fair Value
Profit Margin
4.75%
Future PE
77.25x
Price in 2029
UK£0.09
Trending Discussion
No trending discussion available.
Recently Updated Narratives
AN
Future Clinical Acceptance Of Genetic Risk Scoring Will Support Long Term Earnings Potential
Fair Value: UK£0.075 89.3% undervalued intrinsic discount
1 fair value setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
GENinCode Plc Key Details
Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
n/a
- -0.0076
- 58.65%
- -185.47%
- 0%
About GENI
- Founded
- 2018
- Employees
- 44
- CEO
- WebsiteView website
GENinCode Plc engages in the development and commercialization of clinical genetic tests for predictive analysis of risk to a patient’s health based on genes in the United Kingdom, Spain, Italy, the United States, Germany, and internationally. The company offers CARDIO inCode Score, a genetic test to evaluate the risk of coronary heart disease; LIPID inCode, a genetic test for the diagnosis of familial hypercholesterolemia with further coronary risk stratification of the patient; and SUDD inCode, a genetic diagnostic test for familial heart diseases, such as cardiomyopathies, channelopathies, and aortopathies related with sudden cardiac death syndrome. It also provides THROMBO inCode, a genetic test for the diagnosis of hereditary thrombophilia and for assessing the patient's risk of thrombosis; THROMBO inCode reproductive health, a genetic test that evaluates the impact of hereditary thrombophilia in patients with repeated miscarriages; and risk of ovarian cancer algorithm test product. In addition, the company is involved in Medical and scientific research activities. GENinCode Plc was incorporated in 2018 and is based in Manchester, the United Kingdom.
